Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone-guided extension of goserelin dosing in prostate cancer
NL-OMON54398Phase 4Active, not recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Jul 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of goserelin in prostate cancer (PCa), sponsored by Franciscus Gasthuis & Vlietland. Primary endpoint: Safe 4-week extension before 4th injection. Started Jul 2022; status: active, not recruiting.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON54398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54398.